3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
5
Uterine Cervical Neoplasms
2
Oropharyngeal Neoplasms
2
Hodgkin Disease
2
Cholangiocarcinoma
2
Carcinoma, Hepatocellular
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma
1
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lung Neoplasms
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Leukemia, Plasma Cell
1
Glioma
1
Disease
1
Carcinoma, Squamous Cell
1
Interventions
pembrolizumab
59
Carboplatin
56
Pemetrexed
47
Cisplatin
39
Paclitaxel
24
Nivolumab
23
Docetaxel
21
durvalumab
20
Gemcitabine
15
130-nm albumin-bound paclitaxel
14
osimertinib
13
Cetuximab
12
Specimen Handling
11
Magnetic Resonance Spectroscopy
11
atezolizumab
10
amivantamab
8
Taxes
8
Radiotherapy
8
Radiosurgery
7
Ipilimumab
7
lazertinib
6
alectinib
6
Ramucirumab
6
Observation
6
Bevacizumab
6
cemiplimab
5
Leucovorin
5
Fluorouracil
5
Etoposide
5
Erlotinib Hydrochloride
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
Fluorodeoxyglucose F18
×
30 days
×
Clear all
No trials found.